Literature DB >> 1953818

Single-photon-emission computed tomography of the brain in the evaluation of cerebral lupus.

J C Nossent1, A Hovestadt, D H Schönfeld, A J Swaak.   

Abstract

We sought to determine whether single-photon-emission computed tomography (SPECT) of the brain is useful for detecting abnormalities of regional cerebral blood flow in patients with cerebral lupus. Twenty lupus patients with clinical evidence of cerebral involvement underwent SPECT and CT scanning of the brain, as well as clinical, expert neurologic, and serologic evaluation. Fifteen patients (75%) had a clear regional cerebral hypoperfusion. Seven of 8 patients (88%) who were ultimately thought to have active cerebral lupus had abnormal SPECT scan findings, while 8 of 12 patients (67%) who were ultimately thought not to have active cerebral lupus had abnormal SPECT scan findings. There was no correlation of SPECT findings with CT scan results, overall disease activity, or serologic findings. Regional cerebral blood flow measured by SPECT is often abnormal in patients with active cerebral lupus, but is also frequently abnormal in lupus patients with neuropsychiatric symptoms not attributable to cerebral lupus activity.

Entities:  

Mesh:

Year:  1991        PMID: 1953818     DOI: 10.1002/art.1780341109

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  14 in total

1.  Abnormal brain diffusivity in patients with neuropsychiatric systemic lupus erythematosus.

Authors:  Gerlof P Th Bosma; Tom W J Huizinga; Simon P Mooijaart; Mark A Van Buchem
Journal:  AJNR Am J Neuroradiol       Date:  2003-05       Impact factor: 3.825

2.  Cerebral blood flow abnormalities detected by SPECT in Behçet's-syndrome-related psychiatric disorders.

Authors:  L Mirone; L Altomonte; A Raco; M L Calcagni; V Rufini; A Zoli; M Magarò
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

3.  Blood pressure and vascular dysfunction underlie elevated cerebral blood flow in systemic lupus erythematosus.

Authors:  Charles Gasparovic; Clifford Qualls; Ernest R Greene; Wilmer L Sibbitt; Carlos A Roldan
Journal:  J Rheumatol       Date:  2012-01-15       Impact factor: 4.666

4.  HLA-B27 positive ankylosing spondylitis and polyarteritis nodosa: a case report.

Authors:  M Galeazzi; A Fioravanti; C Minari; E Selvi; M Veronesi; R Marcolongo
Journal:  Clin Rheumatol       Date:  1996-03       Impact factor: 2.980

5.  Perfusion-weighted MR imaging in cerebral lupus erythematosus.

Authors:  Page I Wang; Patricia C Cagnoli; William J McCune; Tobias Schmidt-Wilcke; Suzan E Lowe; Courtney C Graft; Stephen S Gebarski; Thomas L Chenevert; Shokoufeh Khalatbari; James D Myles; Kuanwong Watcharotone; Paul Cronin; Pia C Sundgren
Journal:  Acad Radiol       Date:  2012-05-17       Impact factor: 3.173

6.  Progressive systemic sclerosis and IgA deficiency in a young man.

Authors:  C Veen; A J Swaak
Journal:  Clin Rheumatol       Date:  1993-03       Impact factor: 2.980

7.  Brain single-photon emission tomography with 99mTc-HMPAO in neuropsychiatric systemic lupus erythematosus: relations with EEG and MRI findings and clinical manifestations.

Authors:  P Colamussi; M Giganti; C Cittanti; L Dovigo; F Trotta; M R Tola; R Tamarozzi; G Lucignani; A Piffanelli
Journal:  Eur J Nucl Med       Date:  1995-01

8.  Usefulness of Tc-99m ECD brain SPECT to evaluate the effects of methylprednisolone pulse therapy in lupus erythematosus with brain involvement: a preliminary report.

Authors:  F Y Liu; W S Huang; C H Kao; R F Yen; J J Wang; S T Ho
Journal:  Rheumatol Int       Date:  2003-01-30       Impact factor: 2.631

9.  Central nervous system lupus: concomitant occurrence of myelopathy and cognitive dysfunction.

Authors:  H D Stahl; T H Ettlin; A Plohmann; E W Radü; J Müller-Brand; U Steiger; A Tyndall
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

Review 10.  Neuropsychological impairment in systemic lupus erythematosus: a comparison with multiple sclerosis.

Authors:  R H B Benedict; J L Shucard; R Zivadinov; D W Shucard
Journal:  Neuropsychol Rev       Date:  2008-06-03       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.